
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : SillaJen, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
OSR Holdings and SillaJen Sign MOU to Develop Innovative Therapeutics in US Market
Details : The collaboration will explore various ways to create synergies between current platform technologies and new drug candidates, including BAL0891, a mitotic checkpoint inhibitor targeting solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : BAL0891,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : SillaJen, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
